Partnerships

In June 2011, Sunshine Biopharma entered into a Clinical Trials Agreement with The Jewish General Hospital, one of McGill University’s Hospital Centers, to conduct the necessary research and development to advance Sunshine’s lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials for Top2 Positive Cancers including small-cell lung cancer.

In January 2011, Sunshine Biopharma entered into a collaboration agreement with Binghamton University (Binghamton, NY) to begin conducting the necessary research and development to advance Sunshine’s lead compound, Adva-27a through various stages of preclinical development and Phase I clinical trials for breast cancer and prostate cancer.

The Company is planning to expand its product line through acquisitions and/or in-licensing as well as in-house research & development.

Please submit your non confidential project information to Camille Sebaaly for review and we will do our best to reply within two to four weeks.